IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Launched by INDAPTA THERAPEUTICS, INC. · Oct 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called IDP-023 for patients with advanced blood cancers, such as multiple myeloma and non-Hodgkin lymphoma. Researchers want to find out how safe this treatment is when given alone or in combination with other therapies, like interleukin-2 or certain antibody medications. The goal is to see if IDP-023 can help shrink tumors in patients whose cancer has not responded to previous treatments.

To be eligible for this trial, participants must have a confirmed diagnosis of multiple myeloma or non-Hodgkin lymphoma that has not improved after several past treatments. They should also have a good level of health to participate, meaning they can do normal daily activities with little to no assistance. It’s important for potential participants to know that they will be closely monitored during the trial for any side effects and how well the treatment is working. Overall, this study is a promising step towards finding new options for patients with tough-to-treat blood cancers.

Gender

ALL

Eligibility criteria

• Key Inclusion Criteria:
• • For MM patients: Documented diagnosis of MM requiring systemic therapy and relapsed and/or refractory (R/R) disease after ≥ 3 prior lines of therapy.
• • For NHL patients: R/R disease and failed ≥ 2 lines of systemic chemotherapy.
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• • Life expectancy of greater than 12 weeks per the Investigator.
• Key Exclusion Criteria:
• • Impaired cardiac function or history of clinical significant cardiac disease.
• • Human immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
• • Active SARS-CoV-2 infection.
• • Has untreated central nervous system, epidural tumor metastasis, or brain metastasis.